Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.
Postmenopausal Women With Advanced Breast Cancer
DRUG: Letrozole
Safety during treatment, Until disease progression or appearance of unacceptable toxicity whichever comes first|Response Rate during treatment, Until disease progression or appearance of unacceptable toxicity whichever comes first
Pharmacokinetics measurement at baseline and at every 4 weeks until 28 weeks, Maximum 28 weeks after initiate treatment|Plasma estrogens level at baseline and at every 4 weeks until 28 weeks, Maximum 28 weeks after initiate treatment|Duration of response, From the first date of response confirmed and the last date of response confirmed|Time to progression, From the first date of response confirmed and the last date of response confirmed
To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.